围手术期出血管理中使用凝血因子浓缩物:ISTH SSC围手术期与重症监护血栓与止血委员会的指导意见
围手术期出血仍是大型手术(包括心脏、创伤、产科和器官移植手术)患者致病和资源消耗的主要原因。获得性围手术期凝血病是多因素的,可能由失血、血液稀释、低体温、酸中毒、纤溶、炎症以及凝血因子和血小板消耗引起。过去十年,凝血因子浓缩物因快速可用、标准化给药、输注体积较小和病原体灭活而越来越多地纳入围手术期出血管理流程,减少了对血浆制品的依赖。自2018年ISTH关于围手术期出血凝血因子浓缩物使用指导发布以来,新的临床研究、系统评价和不断演变的出血管理实践扩展了纤维蛋白原浓缩物、凝血酶原复合物、重组活化凝血因子VII和凝血因子XIII浓缩物用于手术获得性凝血病的证据基础。该ISTH围手术期与重症监护小组委员会的指导文件回顾了当前文献,并基于现有证据和专家共识提供围手术期凝血因子浓缩物使用的实用指导。
要点
- 获得性围手术期凝血病是多因素的,可能由失血、血液稀释、低体温、酸中毒、纤溶、炎症以及凝血因子和血小板消耗引起。
- 凝血因子浓缩物因快速可用、标准化给药、输注体积较小和病原体灭活,越来越多地纳入围手术期出血管理流程,减少对血浆制品的依赖。
- 自2018年ISTH指导发布后,新的临床研究、系统评价和实践演变扩展了纤维蛋白原浓缩物、凝血酶原复合物、重组活化凝血因子VII和凝血因子XIII浓缩物用于手术获得性凝血病的证据基础。
- 该指导文件基于现有证据和专家共识,提供围手术期凝血因子浓缩物使用的实用指导。
适用人群与场景
- 接受大型手术的患者,包括心脏、创伤、产科和器官移植手术。
研究设计与关键结果
- 该指导文件由ISTH围手术期与重症监护小组委员会制定,回顾当前文献,并基于现有证据和专家共识提供围手术期凝血因子浓缩物使用的实用指导。
证据类型、等级与局限
- 证据类型:指南/专家共识;基于现有证据和专家共识。
- 局限:原文未报告局限性。
指南或共识出处
- ISTH围手术期与重症监护血栓与止血小组委员会(ISTH SSC Subcommittee on Perioperative and Critical Care Thrombosis and Hemostasis)指导文件,发表于J Thromb Haemost。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「对床旁实践的改变」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Perioperative bleeding remains a major cause of morbidity and resource utilization in patients undergoing major surgery, including cardiac, trauma, obstetrical, and organ transplant surgery. Acquired perioperative coagulopathy is multifactorial and may result from blood loss, hemodilution, hypothermia, acidosis, fibrinolysis, inflammation, and consumption of coagulation factors and platelets. Over the past decade, coagulation factor concentrates have increasingly been incorporated into perioperative bleeding management algorithms because of their rapid availability, standardized dosing, lower infusion volumes, and pathogen inactivation, reducing dependence on plasma products. Since the 2018 publication of the International Society on Thrombosis and Haemostasis (ISTH) guidance on the use of factor concentrates for the management of perioperative bleeding, additional clinical studies, systematic reviews, and evolving bleeding management practices have expanded the evidence base for the use of fibrinogen concentrate, prothrombin complex concentrate, recombinant activated factor (F)VII, and FXIII concentrate for surgically acquired coagulopathy. This guidance document from the Perioperative and Critical Care Subcommittee of the ISTH reviews the current literature and provides pragmatic guidance on the perioperative use of coagulation factor concentrates based on available evidence and expert consensus.
参考来源
- Levy JH, Shaw JR, Siegal DM, et al. Use of factor concentrates for the management of perioperative bleeding: guidance from the ISTH SSC Subcommittee on Perioperative and Critical Care Thrombosis and Hemostasis. J Thromb Haemost. 2026. PMID: 42665231. doi:10.1016/j.jtha.2026.07.030
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。